Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 11.00p 126,802 01:00:00
Bid Price Offer Price High Price Low Price Open Price
10.50p 11.50p 11.00p 11.00p 11.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.77 -0.53 -0.16 22.8

Eden Research (EDEN) Latest News

More Eden Research News
Eden Research Takeover Rumours

Eden Research (EDEN) Share Charts

1 Year Eden Research Chart

1 Year Eden Research Chart

1 Month Eden Research Chart

1 Month Eden Research Chart

Intraday Eden Research Chart

Intraday Eden Research Chart

Eden Research (EDEN) Discussions and Chat

Eden Research Forums and Chat

Date Time Title Posts
22/5/201921:44Eden Research6,342
22/5/201905:07Eden Research; novel encapsulation and delivery technologies454
07/3/201713:47Eden Research- The Natural Solution172
27/2/201611:20Eden Research- The Natural Solution3
18/5/201202:24Eden Research6

Add a New Thread

Eden Research (EDEN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-05-22 14:18:3710.631,755186.47O
2019-05-22 14:05:4511.00100,00011,000.00O
2019-05-22 12:50:1010.605,892624.55O
2019-05-22 11:55:5810.601,441152.75O
2019-05-22 09:21:1710.6017,7141,877.68O
View all Eden Research trades in real-time

Eden Research (EDEN) Top Chat Posts

DateSubject
22/5/2019
09:20
Eden Research Daily Update: Eden Research Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 11p.
Eden Research Plc has a 4 week average price of 10.35p and a 12 week average price of 9.50p.
The 1 year high share price is 14p while the 1 year low share price is currently 9.13p.
There are currently 207,189,337 shares in issue and the average daily traded volume is 41,301 shares. The market capitalisation of Eden Research Plc is £22,790,827.07.
15/5/2019
16:06
investingisatrickygame: Eden, the Snail in the Garden I see Michael Walters has it spot on this time. There is a great deal of frustration around the Eden share price! The problem is that Eden is not allowed to tell common garden investors what is in the shore cap report even though as owners of the company we have paid for it via fees to the brokers! Fairly basic Proactive chats are no substitutions for real projections (that we all can see. Absence of proper broker support available to the private investor! Can the board come up with a new ay of marketing the shares? I have been posting the same on here for years, much to the frustration of some here and on other BB's, but it really is obvious. Perhaps Eden will now listen to Michael Walters. Eden has no traction in the City in regards to buying a position in Eden. Powerscourt who are meant to further the same have made no visible gains. Thus, the Shore Cap report is useless as it falls on deaf ears and a blind audience. They are not looking to see. An independent report by the likes of Edison or whomever similar would have far greater applicable reach to an audience with ears and eyes that will listen, namely the private investor. Furthermore, they are always looking for capital growth and are only restrained by the £ in their pocket, but they will buy and will buy quickly if the story adds up. Shore Caps clients will of course not respond the same. What is the market cap (oh they're too small), they're on AIM (no good), we do invest in green stocks, but none so young as Eden. The reason are extensive and an investment is often a far more complicated decision. Not so with the private investor. Eden does need to find a new way of marketing the shares, but in the first place they need TO MARKET THE SHARES. Eden do not market their shares and their toe in the water with Proactive is merely a series of process updates, albeit well explained, but they never give an investor a reason to buy and consequently, they don't. Eden must surely have learned its lesson over the last 2-3 years in regards to gaining investment in its share price, whom to target, why and how. Everything they have done, which is limited, has failed to incentivise people to invest, but then they have not targeted people (private investors). Eden sits at a market cap of circa £22 million. The narrative and the price still don't align It costs $25-$30 million to deliver a biopesticde to market, so $50-$60 million in total, almost three times our current market cap. The Chairman in the 2018 Annual Report says "the new products in the Company's pipeline aim to address markets which are potentially even bigger that those already covered by its existing products" Also he states " there is potential for an even greater opportunity around the use of Eden's proprietary, natural micro-encapsulation technology which is being teste by a number of third parties including some of the major agchem companies" Where is any of this in a three year forecast from the Company? How is this potential communicated to an investment public outside of this written word in the Annual Report. More importantly, how many people received a hard copy of the Annual Report and how many read/downloaded the PDF. Eden only talks to a few existing investors who are listening. The rest are asleep and the rest of their target audience has no idea who Eden is or the breakthroughs they are making. I very much doubt those not invested in Eden are reading our RNS's, why would they?! So MW is right, find a way to market Eden's shares to an audience that is willing to invest, willing to listen, available to listen and who equally importantly, will be your bag carrier of opportunity to other investors. In my opinion, if we sit here waiting for Powerscourt or a broker to unlock the door then Eden's shares will likely be dormant for some while to come. Finally and for Powerscourt, the world now seems to really understand that Pesticides are bad for you. Eat fruit, veg and nuts everyone; oh dear, they've been treated with pesticides, so maybe 5-a day is not as good for you as we suggested. Eden has a major PR opportunity right in the eye of the storm when readers will listen, journalists will listen and knock on Eden's door, doors will open for Powerscourt as a result of the same, the public will go to Eden's website to find out more, hey they might even invest. Why is Eden not challenging this when their share price is so low, their company value is so undervalued and the newspaper public, I'm sure, would love to hear about them. And it has nothing to do with a small employee base! Eden, one of only a few biocontrol companies globally with proven products and regulatory approval and yet, the investment world knows nothing about it!!!!!
14/4/2019
22:17
investingisatrickygame: Super, Go back and look at the Proactive presentation uploaded on the 12th February 2019 and compare this with the Shore Capital note. From the Proactive presentation:- hxxp://www.edenresearch.com/~/media/Files/E/Eden-Research/documents/reports-and-presentation/eden-presentation-feb-19-proactive.pdf "Globally, Eden is one of the few biocontrol companies with proven products and regulatory authorisation" What value is this if the associated global market opportunities rank so lowly on the Shore Capital note? "The biopesticide market is projected to reach $8.8 billion by 2022" Eden's forecast market share by Shore Capital doesn't appear to resonate with the first statement above made by Eden "Neonicotinoid insecticides were worth $3.1 billion globally but are now facing withdrawal in Europe and elsewhere. Conventional crop protection products formulated with Sustaine and Eden’s active ingredients can help address many of these issues" An Eden statement which is not reflected at all in the Shore Capital note. How is our House Broker understanding Eden's publicly declared statements and therefore representing Eden properly to their investment community? "Eden's proven addressable market is $1.2 billion, tomorrow this grows to more than $2 billion, not including Sustaine" Again, no reflection by Shore Capital of Eden's buoyant and clear statements on opportunity. For example, how does the expected 5% market share projected by Shore Capital align with the above statement? On the last slide, page 28, look at points 2 & 3 which are most imminent and present. Nowhere does the Shore Capital reflect the story that Eden is telling publicly and backing up the Company's own enthusiasm (and let's be honest, Eden is so understated, it's untrue. I find it very frustrating that we, Eden, appear to be at odds with our House Broker whose numbers seem to me to be totally unrepresentative of Eden's current position, likely position in the next 2-3 years (e.g. Cedroz as one example) and pipeline position thereafter. Conventional pesticides are toxic by association, we are told conventional pesticides in some cases are not been renewed by regulators for future sales, bio alternatives is a fast growing market and supported by regulators and undoubtedly the wishes of the public and Eden is one of a few global players. Sustaine is still under evaluation by Sipcam (when do we get updated), it is a game changer according to Xinova (hxxps://www.xinova.com/work/eden-research/), Bayer Crop Science evaluating the same and likely others as indicated and we get a £50 million valuation from Shore Capital, maybe up to £98 million. Eden needs to put this right, surely. It was stated in the original Proactive presentation that Eden would deliver new forecasts to the market, through who? I believe these forecast are due in the next 8 weeks or so from memory. You cannot expect shareholders to keep getting slapped in the face, sitting in a static share price and expect them to stay invested in any "sustainable" way. It's not good for private investors and it's not good for Eden as a business.
08/2/2019
13:30
investingisatrickygame: I didn't attend the presentation last evening, but what I take from it is as follows:- Source: [...] 1)It is the best, most specific, most relevant presentation that I have seen Eden deliver 2)Slide 3 "globally, Eden is one of the few biocontrol companies with a proven business". Based on this alone and referencing back to the Chairman's comments at the 2018 AGM, then it is nailed on that Eden is high and maybe even imminent in terms of actioning anything on such companies watchlist. So specifically, taking a stake, taking out a vertical, taking out Eden altogether 3)Slide 8, it would have been good to see more detail on Consumer Products as this part of the slide has been produced many times with little or no visible progress, head lice aside 4)Slide 11, finally qualified the annual value (2022 anticipated) of the biopesticide market & will be attacking the $3.1 billion neonicotinoid market through Sustaine encapsulation and co-encapsulation 5) Slides 9 & 12 somewhat qualify their intent to deliver in the 'slug' market 6) Slide 19 "Unique technology". How will anyone value that? Very interesting if they can clearly show a path to Sustaine helping them in their goal of being the "leader in sustainable bioactive products". Given the global statement in point 2 above, how far away is Eden from that now? With their distribution partners, what timeframe is likely to achieve that? Does this therefore increase focus on Eden now from industry players and does that heighten the potential for a hostile, or otherwise, bid? 7)Slide 20, Eden has qualified the value of their proven addressable biopesticide market; $1.2 billion, 14% of the global market projected value 8) Slide 21, Eden finally qualifies themselves that the entry to market is both time consuming and very expensive (previously not stated by Eden, but by chemical companies such as Syngenta). With biopesticides development costing 10% of that of traditional chemicals, with Eden established and again, point 2 above, that to me does again, place Eden front and central as a potential takeover/stake building target 9)Slide 26 UPDATED MARKET FORECASTS to be published during H1 2019. When were they ever publicly available? This sounds like a major step to me in terms of visibility to value. Via Eden, Edison or ANO? 10) Slide 29 Bayer Animal Health commercial launches. When? We've heard this so many times so a bit more underpinning and conviction to reassure everyone that it will finally happen would be worthwhile, assuming that wasn't given in speech last night. Best in print though so everyone can see when this presentation gets shared with others. Also "Accelerate commercialisation of Sustaine for conventional actives. So Sustaine encapsulation of others commercial chemical products. We could do with a more in-depth update on this in regards to Eden's evaluation agreement on the same with Sipcam It is the best and most convincing Eden presentation I have seen, underpinned by numbers, targets and soon to be, forecasts. As ChrisChas said, Eden needs to build upon this, re-emphasise this, broaden this and message to as wide a relevant audience as possible. Use film to cover this as it is more digestible and when delivered well, making Eden more investible. How much is an industrial tech company that has unique technology and is globally, one of the few bioactive companies with a proven business, worth? 12 years and $300 million cost is too long to wait as the train has left the station. Regulatory pressures going against traditional chemicals combined with the two points above makes Eden a no-brainer. So the stand out point in the presentation that makes no sense to private investors, hopefully makes no sense to institutional investors and I'm sure looks crazy to industry players is slide 3....Eden Market Cap £20 million Eden is so undervalued for investors and potential suitors alike that if Eden's share price was a £1 today, it wouldn't look stupid!!!!!!!!!!!
05/2/2019
13:05
investingisatrickygame: Hi Super, Protective peace of mind for investors would be good, if you are staying invested for years AND if you think the shares can one day be worth, £1, £2 or more. However, if you don't think management can carry the business to deliver that value (and the share price has carried no value this last two years, even allowing for Sipcam's strategic investment and Eastmans contract for 29 major countries) or if you think that an industry player will not let Eden accrue that value, then in my opinion on share price, there is little to protect. Rather than dilute a share price that based on trend with new alliances and commercial contracts has travelled nowhere, I would rather see Eden attract new money through commercial arrangements and then leave the issued share capital at 207 million shares and hopefully see the share price move north from here. Eden needs to light the touch paper for the shares to rise. Thursday night should be an attempt at lighting the touch paper. In the absence of new news and given Eden has chosen to present, then the theme of their presentation ought to be 'why should you invest today in Eden Research'. If they do not satisfy that criteria, then one of the three other presenters will attract money into their Company or investors will look elsewhere and Eden will be remembered by the attending audience as a Company who didn't warrant investment of my hard earned capital. Those memories linger and get shared with others. So Eden is not only presenting to those in attendance, but all those that attendee's share with via word of mouth and all those that will see and read the Eden presentation. I think the evening has to be about why we are a good place for your money. That is what will help drive the share price and the word of mouth to encourage others!
02/2/2019
12:31
investingisatrickygame: Upcoming Week I think it is a big week in store for Eden. A non-performing share price for the last two years, it has sat in a very narrow and arguably low range. Shareholders have had no returns and given this is their intended outcome, I'm sure many will seek inspiration from this coming Thursday's inaugural investor audience presentation. I ask myself why are they doing this now? If it is to tell the story as is to a live audience then I personally would be very disappointed. I am hoping for, almost expecting positive RNS's this week. When Eden does announce via RNS the Bayer, TT, Sustaine announcements they (failing another strategic investment/partnership) will have delivered their last major RNS's for a while, at least to my mind. Therefore, when these announcements do come, they need some fanfare; what do they really mean for the Company; how will this leverage other aligned developments; what is the value of these deals; where does this place Eden? It's a terrific opportunity to really explain the value of Eden to everyone and this will need to be done for the share price to positively transform. We will of course have updates on Mevalone US and Cedroz companies coming on stream. These are all the value makers that sit before Eden and their shareholders right now. So I keep asking myself, what is the value of all of the above? This is what I want Eden to tell me, you and anyone and everyone who is willing to listen. With all of this in place and if not translated into the share price, why would Eden not be a bid target? Their share price in this scenario would be one of continuous underperformance and therefore would be available cheaply to an interested party with significant and imminent oncoming income streams. So potentially, a big week for Eden and to have investors understand all of this and to get the share price climbing. If not, then as an investment Eden to me would seem to be in limbo.
25/1/2019
07:47
wan: Clearly both the CEO and the FD need catalysts for their LTIP options to vest - In respect of 2015: · To the CEO Sean Smith nil cost options over 1,098,680 ordinary shares. · To the CFO Alex Abrey nil cost options over 810,000 ordinary shares. The vesting date of the options is 30 September 2019, and they only become exercisable if the following share price performance conditions are met: 50% of the options become exercisable if the weighted average Ordinary Share price in the 45 day period ending on the vesting date is £0.20 or above. Between weighted average ordinary share prices of £0.20 and £0.30, vesting shall be pro-rata and on a straight line basis between 50% and 100%. Below £0.20 the options are not exercisable and lapse in full. In respect of 2016: · To the CEO Sean Smith nil cost options over 1,148,000 ordinary shares. · To the CFO Alex Abrey nil cost options over 960,000 ordinary shares. The vesting date of the options is 30 September 2020, and they only become exercisable if the following share price performance conditions are met: 50% of the options become exercisable if the weighted average Ordinary Share price in the 45 day period ending on the vesting date is £0.24 or above. Between weighted average Ordinary Share prices of £0.24 and £0.36, vesting shall be pro-rata and on a straight line basis between 50% and 100%. Below £0.24 the options are not exercisable and lapse in full. hTTp://otp.investis.com/clients/uk/eden_research/rns/regulatory-story.aspx?cid=2240&newsid=933257 The options may lapse of course, and they then may be just as frustrated as some of their shareholders are! What I am sure about is that reaching those share price targets is about more than just simply getting the Eden message out! In my opinion only, and in order to deliver on a number of fronts, I think there needs to be a strategic event that will take Eden to the next level (and hopefully that will also help deal with Bayer, use it or lose it! and indeed TerpeneTech). Time will of course tell.
24/1/2019
11:34
investingisatrickygame: GM Wan You make some interesting points "Are you saying you want a PR firm to put another spin on the potential/jam tomorrow stuff?" AND "Not all investors want the level of risk that a very small company like Eden currently presents, but when that changes or indeed starts to change, we should see a notable change" JAM TOMORROW I for one do not want any 'spin'. Equally, I am not interested today in Eden spouting their long list of patents which for most invested today, given lab and field trial times and regulatory approval leading to being on sale will have no material effect on their share price returns. Some of that may be 5 years away and many here will not be invested in Eden for the next 5 years! So, what is Eden all about and what is happening yesterday and today that will give me an investment return tomorrow, next week, next month and this year. You see, I'm tired having been in this for many years already and I am fed up of hearing about jam tomorrow. That story has been told one too many times!!!! LEVEL OF RISK I totally get that some will not want the level of risk that is associated with a company such as Eden and as such, they will not want to listen and they will not want to invest. However, what is the level of risk in investing in Eden today at 11-12p? Perhaps management should explain why Eden is fully de-risked at this price range so as to have potential investors understand Eden and the possible shareholder returns! This is a major part of delivering an investor communications programme to the same audience and this IS NOR PR, spin or any other like output. IS EDEN DE-RISKED AT 11-12P? 1) What is the value of Eden's IP? I am not talking about in Eden's balance sheet, I am talking about to other players on the agro-chemicals/biologicals markets. Here is an example of a products life journey to market and one which I am sure both you and Eden are familiar with hxxps://www.syngenta.com/how-we-do-it/research-and-development/how-we-make-new-products. The value line from 11p to somewhere along this path is in part, what needs to be conveyed to investors 2) What is the value of the Mevalone distribution rights & associated projected sales over the next 3 years? 3) What is the value of Cedroz distribution rights and associated projected sales over the next three years? 4) What is the value of TT headlice distribution rights and associated value of the next three years? A) When Bayer is shortly confirmed, what is the value of the Bayer distribution rights and associated value over the next three years? B) When Sipcam announces via Eden its findings on Sustaine encapsulation of Sipcam's current commercialised products and co-encapsulation opportunities with Eden's active ingredients, what will be the value of those tech rights over the next three years? If I was building the investment case in Eden via an Investor Communications programme, I would start at the very beginning introducing Eden, its management, its product and tech and come right through to the present on points 1-4 so that there was no spin, no PR, just a good solid understanding of the Company, what is does, Managements suitability for purpose and the audience would readily understand Eden's current income and value, three year projected forward income and value and would make their own decisions about 11p. I guarantee you, it would not stay at 11p for very long once all of that was delivered. I would also underpin the same programme of delivery with a research paper from Edison Research because they, better than anyone else, can deliver the same, reach out around the world and MOST IMPORTANTLY, ensure that Eden's current target audience can see the same and understand it, namely, private investors. Shore Capital et al are not allowed to deliver such papers to you and I to absorb and the audience they go to are not currently interested in Eden. When they are, fair enough. Walbrook PR, Powerscourt PR and all the others WILL NOT deliver this programme because they do not have the inclination to do so, the time, they would charge Eden too much, yet still (in my experience and opinion) not understand it. So in summary, I agree with you. Eden does not need PR, but at 11p it is de-risked to a share price level much higher than today. If the share price gets beyond itself, then again an investment would be a risk. However, in my opinion, 11p is so far away from risk, that it really is time management, if they believe the same, did the right thing and put the share price on a proper footing. If they feel they can't do it themselves (and their PR firms definitely can't), then find someone who can ( and I am not talking about me before anyone offers that commentary up)!
02/1/2019
15:13
jaknife: Are we forecasting for the EDEN share price? Put me down for 2p by Xmas please. JakNife
19/11/2018
13:47
investingisatrickygame: Super, Post 4904 is a brilliant find. I don't know where you find this stuff, but well done. Undeniably Eden, but like revenue stream many years in the future BACK TO THE PRESENT - RNS's DUE How on earth is Eden going to release up to 19 due RNS's by the 31st December 2018 and give them all the due credit, time, explanation, education and reach that they deserve, both within and beyond the RNS announcements themselves? How are they all going to make their relative impact and what will Eden & Powerscourt do to ensure this becomes a reality. There are circa 24+ working days left and no doubt the City will knock off early, in reality meaning less meaningful days as far as a Plc is concerned, mistakenly so in my opinion in AIM Stocks such as Eden which a primarily driven by you and me. Releasing such a slurry of news pre-Christmas also opens Eden up to a peak and trough with some taking rare profits in time for Christmas, should the share price spike in Eden. Eden appears to be leaving these all to the last minute which if so, is not good management of the same, if indeed this is taking place. With Eden telling us that there is such a small management team to address these news issues and investor communications, can they really afford not to pay due time and attention to these key RNS's that have been so long in the waiting? Eden can't afford to be a yo-yo share when news comes out. No one wants great prospects and then total insecurity in the share price when it should trade with less volatility. We're back to, in my opinion, that Eden must have a plan and they must execute it well. RNS's are not here to be thrown away. 14 have been released this calendar year and the share price has done nothing. There really is no more time to be bewildered by the share price and the lack of interest and corporate (Eden) value in the Mcap. It is time to take the share price seriously and deliver its associated value. To not do so is negligent in my opinion. Plc's reflect their corporate value within their share price. That is a fundamental reason for being listed; to create and deliver value. If Eden is waiting for parties to commit/sign on the dotted line or similar and know it is coming, then they have the knowledge and should create the time to deliver news more fully. RNS's and associated newsflow in the past has not been complementary to events. Eden has learned this and feedback from shareholders has said the same. How can Eden not deliver from all of the above knowledge and experiences, right this time, first time on this mass of key corporate news!
04/9/2018
15:50
investingisatrickygame: Who sells 100,000 shares today at 10.58p when Eden says The interims will be published in the coming weeks (September) TT to deliver income in 2018 Bayer will do the same in 2018 Multiple Sipcam updates on co-encapsulation, distribution rights & more Eastman update Appointment of a US distributor for Mevalone (mentioned 21/3/2018, Proactive Video) PLUS anything else that has not yet been made public knowledge. Unless under severe financial stress, surely Eden can do more to protect investors from themselves. Surely there should be a lead into all of the above, updates, communication. The Eden share price needs a band aid until such time as it is healthy enough to look after itself!!!!!!
Eden Research share price data is direct from the London Stock Exchange
Your Recent History
LSE
EDEN
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190522 23:01:05